Bulletin
Investor Alert

New York Markets Close in:

Market Pulse Archives

Feb. 3, 2020, 7:20 a.m. EST

GW Pharma submits supplemental NDA for Epidiolex to treat seizures from TSC

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GW Pharmaceuticals PLC ADR (GWPH)
  • X
    ETFMG Alternative Harvest ETF (MJ)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

GW Pharmaceuticals PLC /zigman2/quotes/209686240/composite GWPH -2.25% said Monday it has submitted a supplemental New Drug Application (NDA) to expand the label for Epidiolex cannabidiol oral solution, CV, to include the treatment of seizures associated with Tuberous Sclerosis Complex (TSC). Epidiolex is currently indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). "The submission of this sNDA for Epidiolex is an important step towards the prospect of offering a new treatment option for those patients with TSC who battle difficult-to-treat seizures," said Chief Executive Justin Gover. GW's stock, which is still inactive in premarket trading, has tumbled 15.3% over the past three months, while the ETFMG Altnerative Harvest ETF /zigman2/quotes/204332491/composite MJ -1.51% has dropped 15.6% and the S&P 500 /zigman2/quotes/210599714/realtime SPX -1.25% has gained 5.2%.

/zigman2/quotes/209686240/composite
US : U.S.: Nasdaq
$ 99.71
-2.30 -2.25%
Volume: 330,648
Sept. 18, 2020 1:17p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$3.18 billion
Rev. per Employee
$20,686
loading...
/zigman2/quotes/204332491/composite
US : U.S.: NYSE Arca
$ 11.12
-0.17 -1.51%
Volume: 456,457
Sept. 18, 2020 1:19p
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,315.10
-41.91 -1.25%
Volume: 1.50B
Sept. 18, 2020 1:20p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.